Paris Roidos
Research Subjects
Paris Roidos has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Amir Abdollahi
Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ), Heidelberg, Germany
2 shared publications Adrian M. Stütz
European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany
1 shared publicationAliaksandr Halavatyi
1 shared publicationAnna Baginska
1 shared publication- Balca R Mardin1 shared publication
- Balca R. Mardin
BioMed X Institute (GmbH), Heidelberg, Germany
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by Springer Nature in Hormones
- Vol. 25 (2) , 527-533
Genetic background of obesity: a case-control study
Purpose: The rising prevalence of obesity and type 2 diabetes mellitus (T2DM) constitutes a major global public health concern. Increasing evidence indicates that genetic polymorphisms may modulate the risk of T2DM in individuals with obesity, providing valuable insight into the biological pathways that connect these interrelated disorders. A better understanding of the genetic determinants underlying obesity-associated T2DM could enhance disease characterization and inform risk stratification strategies. The genetic architecture linking obesity and T2DM has, however, not yet been fully elucidated. Materials and methods: In this case-control study, we investigated the distribution of the TCF7L2 rs7903146, FTO rs9939609, and PPARG rs1801282 polymorphisms in 257 Greek adults with obesity (BMI > 30 kg/m²), including 136 individuals without T2DM and 121 with T2DM. The primary prespecified analysis applied unadjusted additive logistic regression to estimate per-allele odds ratios (ORs) for T2DM risk, while dominant and recessive inheritance models were evaluated as secondary analyses. Hardy-Weinberg equilibrium was assessed in the control group using an exact test. In participants without diabetes, genotype distributions were further compared across clinically defined HbA1c categories based on American Diabetes Association thresholds. The study was conducted and reported in accordance with STREGA guidelines. Results: Genotype distributions differed significantly between cases and controls for all three loci. In the additive model, each additional T allele at TCF7L2 rs7903146 was associated with higher odds of T2DM (OR 2.66, 95% CI 1.92–3.68; p < 0.001). Similar associations were observed for FTO rs9939609 (OR 1.52, 95% CI 1.14–2.03; p = 0.005) and PPARG rs1801282 (OR 1.98, 95% CI 1.41–2.77; p < 0.001). No statistically significant association was detected between the examined variants and HbA1c category in the non-diabetic group. In controls, all three loci deviated from HWE, with marked heterozygote deficits for TCF7L2 and FTO. Conclusions: TCF7L2 rs7903146 and FTO rs9939609 were associated with T2DM among individuals with obesity in this cohort, whereas PPARG rs1801282 showed an association in the opposite direction from that reported in much of the prior literature. These findings should be interpreted cautiously because the regression models were unadjusted, while the control-group HWE deviations raise concerns regarding assay or sampling validity. Larger, well-characterized studies with participant-level covariate data and expanded quality-control procedures are required.
- 2 June 2026
- Published by Springer Nature in Hormones
- Vol. 25 (2) , 527-533
Open AccessGenetic background of obesity: a case-control study
Purpose: The rising prevalence of obesity and type 2 diabetes mellitus (T2DM) constitutes a major global public health concern. Increasing evidence indicates that genetic polymorphisms may modulate the risk of T2DM in individuals with obesity, providing valuable insight into the biological pathways that connect these interrelated disorders. A better understanding of the genetic determinants underlying obesity-associated T2DM could enhance disease characterization and inform risk stratification strategies. The genetic architecture linking obesity and T2DM has, however, not yet been fully elucidated. Materials and methods: In this case-control study, we investigated the distribution of the TCF7L2 rs7903146, FTO rs9939609, and PPARG rs1801282 polymorphisms in 257 Greek adults with obesity (BMI > 30 kg/m²), including 136 individuals without T2DM and 121 with T2DM. The primary prespecified analysis applied unadjusted additive logistic regression to estimate per-allele odds ratios (ORs) for T2DM risk, while dominant and recessive inheritance models were evaluated as secondary analyses. Hardy-Weinberg equilibrium was assessed in the control group using an exact test. In participants without diabetes, genotype distributions were further compared across clinically defined HbA1c categories based on American Diabetes Association thresholds. The study was conducted and reported in accordance with STREGA guidelines. Results: Genotype distributions differed significantly between cases and controls for all three loci. In the additive model, each additional T allele at TCF7L2 rs7903146 was associated with higher odds of T2DM (OR 2.66, 95% CI 1.92–3.68; p < 0.001). Similar associations were observed for FTO rs9939609 (OR 1.52, 95% CI 1.14–2.03; p = 0.005) and PPARG rs1801282 (OR 1.98, 95% CI 1.41–2.77; p < 0.001). No statistically significant association was detected between the examined variants and HbA1c category in the non-diabetic group. In controls, all three loci deviated from HWE, with marked heterozygote deficits for TCF7L2 and FTO. Conclusions: TCF7L2 rs7903146 and FTO rs9939609 were associated with T2DM among individuals with obesity in this cohort, whereas PPARG rs1801282 showed an association in the opposite direction from that reported in much of the prior literature. These findings should be interpreted cautiously because the regression models were unadjusted, while the control-group HWE deviations raise concerns regarding assay or sampling validity. Larger, well-characterized studies with participant-level covariate data and expanded quality-control procedures are required.
- Open Access
- 14 August 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-15
A scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice
Double-strand breaks (DSBs) are the most toxic type of DNA lesions. Cells repair these lesions using either end protection- or end resection-coupled mechanisms. To study DSB repair choice, we present the Color Assay Tracing-Repair (CAT-R) to simultaneously quantify DSB repair via end protection and end resection pathways. CAT-R introduces DSBs using CRISPR/Cas9 in a tandem fluorescent reporter, whose repair distinguishes small insertions/deletions from large deletions. We demonstrate CAT-R applications in chemical and genetic screens. First, we evaluate 21 compounds currently in clinical trials which target the DNA damage response. Second, we examine how 417 factors involved in DNA damage response influence the choice between end protection and end resection. Finally, we show that impairing nucleotide excision repair favors error-free repair, providing an alternative way for improving CRISPR/Cas9-based knock-ins. CAT-R is a high-throughput, versatile assay to assess DSB repair choice, which facilitates comprehensive studies of DNA repair and drug efficiency testing.
- 14 August 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-15
Open AccessA scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice
Double-strand breaks (DSBs) are the most toxic type of DNA lesions. Cells repair these lesions using either end protection- or end resection-coupled mechanisms. To study DSB repair choice, we present the Color Assay Tracing-Repair (CAT-R) to simultaneously quantify DSB repair via end protection and end resection pathways. CAT-R introduces DSBs using CRISPR/Cas9 in a tandem fluorescent reporter, whose repair distinguishes small insertions/deletions from large deletions. We demonstrate CAT-R applications in chemical and genetic screens. First, we evaluate 21 compounds currently in clinical trials which target the DNA damage response. Second, we examine how 417 factors involved in DNA damage response influence the choice between end protection and end resection. Finally, we show that impairing nucleotide excision repair favors error-free repair, providing an alternative way for improving CRISPR/Cas9-based knock-ins. CAT-R is a high-throughput, versatile assay to assess DSB repair choice, which facilitates comprehensive studies of DNA repair and drug efficiency testing.
- Open Access
- 1 December 2019
- Published by Springer Nature in Molecular Systems Biology
- Vol. 15 (12)
A solid‐phase transfection platform for arrayed CRISPR screens
Arrayed CRISPR‐based screens emerge as a powerful alternative to pooled screens making it possible to investigate a wide range of cellular phenotypes that are typically not amenable to pooled screens. Here, we describe a solid‐phase transfection platform that enables CRISPR‐based genetic screens in arrayed format with flexible readouts. We demonstrate efficient gene knockout upon delivery of guide RNAs and Cas9/guide RNA ribonucleoprotein complexes into untransformed and cancer cell lines. In addition, we provide evidence that our platform can be easily adapted to high‐throughput screens and we use this approach to study oncogene addiction in tumor cells. Finally demonstrating that the human primary cells can also be edited using this method, we pave the way for rapid testing of potential targeted therapies.
- 1 December 2019
- Published by Springer Nature in Molecular Systems Biology
- Vol. 15 (12)
Open AccessA solid‐phase transfection platform for arrayed CRISPR screens
Arrayed CRISPR‐based screens emerge as a powerful alternative to pooled screens making it possible to investigate a wide range of cellular phenotypes that are typically not amenable to pooled screens. Here, we describe a solid‐phase transfection platform that enables CRISPR‐based genetic screens in arrayed format with flexible readouts. We demonstrate efficient gene knockout upon delivery of guide RNAs and Cas9/guide RNA ribonucleoprotein complexes into untransformed and cancer cell lines. In addition, we provide evidence that our platform can be easily adapted to high‐throughput screens and we use this approach to study oncogene addiction in tumor cells. Finally demonstrating that the human primary cells can also be edited using this method, we pave the way for rapid testing of potential targeted therapies.